BIO FOr CARE: biomarkers of hypertrophic cardiomyopathy development and progression in carriers of Dutch founder truncating MYBPC3 variants—design and status

[1] Elliott PM(2014)2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC) Eur Heart J 35 2733-2779

[2] Anastasakis A(2018)Prospective countywide surveillance and autopsy characterization of sudden cardiac death: POST SCD study Circulation 137 2689-2700

[3] Borger MA(2017)Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy Circ Res 121 749-770

[4] Tseng ZH(1995)Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA study. Coronary artery risk development in (young) adults Circulation 92 785-789

[5] Olgin JE(2015)New perspectives on the prevalence of hypertrophic cardiomyopathy J Am Coll Cardiol 65 1249-1254

[6] Vittinghoff E(2003)Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy Circulation 107 2227-2232

[7] Marian AJ(2018)Outcomes of contemporary family screening in hypertrophic cardiomyopathy Circ Genom Precis Med 11 e001896-1928

[8] Braunwald E(2015)Hypertrophic cardiomyopathy in adulthood associated with low cardiovascular mortality with contemporary management strategies J Am Coll Cardiol 65 1915-848

[9] Maron BJ(2010)The yield of risk stratification for sudden cardiac death in hypertrophic cardiomyopathy myosin-binding protein C gene mutation carriers: focus on predictive screening Eur Heart J 31 842-2020

[10] Gardin JM(2014)A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD) Eur Heart J 35 2010-355

[1] Elliott PM(2014)2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC) Eur Heart J 35 2733-2779

[2] Anastasakis A(2018)Prospective countywide surveillance and autopsy characterization of sudden cardiac death: POST SCD study Circulation 137 2689-2700

[3] Borger MA(2017)Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy Circ Res 121 749-770

[4] Tseng ZH(1995)Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA study. Coronary artery risk development in (young) adults Circulation 92 785-789

[5] Olgin JE(2015)New perspectives on the prevalence of hypertrophic cardiomyopathy J Am Coll Cardiol 65 1249-1254

[6] Vittinghoff E(2003)Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy Circulation 107 2227-2232

[7] Marian AJ(2018)Outcomes of contemporary family screening in hypertrophic cardiomyopathy Circ Genom Precis Med 11 e001896-1928

[8] Braunwald E(2015)Hypertrophic cardiomyopathy in adulthood associated with low cardiovascular mortality with contemporary management strategies J Am Coll Cardiol 65 1915-848

[9] Maron BJ(2010)The yield of risk stratification for sudden cardiac death in hypertrophic cardiomyopathy myosin-binding protein C gene mutation carriers: focus on predictive screening Eur Heart J 31 842-2020

[10] Gardin JM(2014)A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD) Eur Heart J 35 2010-355